多西他赛联合顺铂同步放疗治疗非小细胞肺癌近期疗效观察被引量：3

Short-term efficacy and safety of concurrent docetaxel and cisplatin combined with radiotherapy for patients with non-small-cell lung cancer

下载PDF

导出

摘要目的评价多西他赛联合顺铂同步放疗治疗不能手术切除的局部晚期非小细胞肺癌(non-small-cell lungcancer,NSCLC)的近期疗效和急性不良反应。方法 120例患者随机分为两组,其中同步放化疗组60例,采用多西他赛联合顺铂同步放疗。放疗采用6/15 MV X线,每周照射5次,每次200 cGy,共治疗4周;有锁骨上淋巴结转移者,给予X线和电子线混合照射至DT 60～66 Gy。在放疗开始后的1、8、15 d,于放疗前4 h给予多西他赛20～25 mg/m2,顺铂40 mg/m2化疗。单纯放疗组60例,治疗方法与同步放化疗组的放疗方法相同。结果同步放化疗组与单纯放疗组有效率分别为90.0%和70.0%(P<0.05);两组不良反应主要为骨髓抑制、胃肠道反应、放射性食管炎、放射性肺炎和肝功能受损等,经处理后均可耐受,差异无统计学意义。结论多西他赛联合顺铂有放疗增敏作用,较单纯放疗能够提高NSCLC近期疗效,急性不良反应增加不明显。 Objective To evaluate the feasiblity and safety of combined docetaxel and cisplatin chemotherapy with a sensitizer and concurrent radio - chemotherapy in stage m NSCLC. Methods Sixty patients with inoperable stage Ill NSCLC were treated with doeetaxel, cisplatin and radiotherapy. Chemotherapy consisted of intravenously docetaxel 20 -25 mg/m2 on days 1, 8, 15, cisplatin 40 mg/m2 on days 1 , 8, 15. Radiotherapy was delivered up to a total dose of 66 -70 Gy with a 2.0 Gy dose fraction per day, 5 days per week. Sixty patients underwent radiotherapy. Results The overall response rates of primary tumors and mediastinum metastatic nodes were 90.0% and 70.0% , respectively （P 〈 0.05）. The acute side effects in patients were mostly myelosuppression, nausea, vomi- ting, radiation induced esophagitis and pneumonitis, and liver toxicity. However, all of them were tolerant. Conclusions Combined chemo -radiotherapy has good response and survival as compared with conventional radiotherapy in the treatment of locally advanced non - small - cell lung cancer without aggravating the side effects. Docetaxel and cisplatin should be used as a radiosensitizer.

作者袁慧欣耿丽李惠媛

机构地区武警山西总队医院

出处《武警医学》 CAS 2013年第3期192-194,共3页 Medical Journal of the Chinese People's Armed Police Force

关键词非小细胞肺癌多西他赛顺铂放疗 non - small - cell lung cancer docetaxel cisplatin radiotherapy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献5

1Hwang A, Muschel R J. Radiation and the G2 phase of the cell cycle [ J ]. RadiatRes, 1995, 150 ( Suppl 5 ) : 852 - 859.
2Dunne A L, Mothersill C,Robson T, et al. Radiosensitiza- tion of colon cancer cell lines by docetaxel mechanisms of action [ J ]. Oncol Res, 2004,14 ( 9 ) :447 - 454.
3Koolen S L, Beijnen J H, Schellens J H. Intravenous - to -oral switch in anticancer chemotherapy:a focus on do- eetaxel and paclitaxel [ J ]. Clin Pharmacol Ther,2010,87 (1) :126 -129.
4郑爱青,郑培,于金明,穆海玉,朱新英.吉西他滨单药或联合卡铂治疗老年晚期非小细胞肺癌疗效观察[J].武警医学,2011,22(6):501-504. 被引量：7
5蒋国良.现代肿瘤放射治疗学[M]. 上海:上海科学技术出版社,2003:461.

二级参考文献9

1Gridelli C, Maione P, Rossi A, et al. Treatment of locally advanced non - small cell lung cancer in the elderly [J]. Curr Opin Oncol,2005,17(2) :130 -134.
2Cheong K A, Chrystal K, Harper P G. Management of the elderly patient with advanced non - small cell lung cancer[J]. Int J Clin Pract. 2006, 60(3):340 -343.
3Hogberg T,Glimelius B. Nygren P. A systematic overview of chemotherapy effects in non - small cell lung cancer [ J ]. Acta Oncologica. 2001,40 (2) : 1327 - 1329.
4Hinton S,Sandler A. Lung cancer in the elderly 1 current and future chemotherapeutic options [J]. Drugs Aging, 2002,19 (5) :365 -375.
5Sandler A, Ettinger D S. Gemcitabine: single - agent and combination therapy in non - small cell lung cancer. Oncologist. 1999; 4(3) :241 -251.
6Socinski M A. Clinical issues in the management of non -small - cell lung cancer and the role of platinum - based therapy[ J ]. Clin Lung Cancer, 2004, 5 (5) :274 - 289.
7Manegold C. Gemcitabine (Gemzar) in non -small cell lung cancer [J]. Expert Rev Anticancer Ther, 2004, 4 ( 3 ) :345 - 360.
8Bennett C L. Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer[ J]. Crit Rev Oncol Hematol,2003,48 ( Suppl ) : S71 - 74.
9闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913-1915. 被引量：8